Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. The Centers for Disease Control and Prevention estimates that around 1 in 50 people in the U.S. carried MRSA in their noses as of August 2019. Furthermore, these individuals are four times more susceptible to infection. MRSA is commonly found in hospitals and healthcare facilities and it can cause severe health problems such as pneumonia, bloodstream infections, sepsis, and even death. The MRSA infection can be tested with the help of test kits, instruments, reagents and software. New DNA-based tests are fast, however they have proven to be cost-prohibitive for widespread use. Traditional methods rely on time-consuming culture techniques which require 48 hours to exclude MRSA and several days to confirm positives. However, these allow hospitals to affordably implement screening to help optimize patient outcomes and mitigate the risks associated with cross-contamination.

The Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems market is estimated to be valued at US$ 105.08 million in 2020 and is expected to exhibit a CAGR of 10.5% during the forecast period (2020-2027).

Fig. 1 Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market Share (%) Analysis, By Product, 2020

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems  | Coherent Market Insights

The increasing prevalence of methicillin resistant staphylococcus aureus infection as well as approvals for products developed by market players are expected to drive growth of the methicillin resistant Staphylococcus aureus (MRSA) testing systems market.

The growing prevalence of methicillin resistant Staphylococcus aureus infection worldwide is expected to drive growth of the methicillin resistant Staphylococcus aureus (MRSA) testing systems market. According to the U.S. Department of Health and Human Services report of March 2019, nearly 120,000 staphylococcus aureus bloodstream infections and 20,000 associated deaths occurred in the U.S. in 2017. After years of slow progress, the rate of decline of MRSA bloodstream infections has slowed, but bloodstream infections caused by methicillin-susceptible S. aureus in hospitals are increasing day by day in the community.

Moreover, products approvals by regulatory bodies are expected to accelerate the Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems market growth in the near future. For instance, in October 2019, Luminex Corporation announced that the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the ARIES MRSA Assay. The assay is an integrated, real-time, polymerase chain reaction (PCR) based, qualitative, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. The Luminex ARIES System is a real-time instrument designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into the modern laboratory.

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market - Restraints

However, growth of the methicillin resistant staphylococcus aureus (MRSA) testing systems market may be hampered owing to the increasing product recalls of methicillin resistant staphylococcus aureus (MRSA) testing systems in the market. For instance, in August 2019, the U.S. FDA initiated a product recall on Becton Dickinson & Company’s BD Max MRSA test kit because the foil bags containing extraction tubes for BD MAX Reagent products may not be sealed properly which can lead to false representation of test results. An advisory has been released to all the users of BD Max instruments within testing facilities to ensure awareness and prevent false test results.

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market – Regional Analysis

North America accounted for the largest share in the methicillin resistant staphylococcus aureus (MRSA) testing systems market, in 2019 owing to the increasing number of mergers and acquisitions in the U.S. For instance, in April 2017, Avantor Performance Materials, LLC, announced the acquisition of Puritan Products, Inc., a supplier of cGMP buffers and solutions for Biopharma customers, and high-purity chemistries for Research and Electronic Materials customers. The acquisition of the Puritan Products brand expanded Avantor’s cGMP operations, improved supply chain security, and provided new teams experienced in high-purity materials manufacturing such as J.T.Baker, Macron Fine Chemicals, Puritan MRSA Transport Medium and Puritan brands of high-purity products and packaging for Avantor to become more agile and responsive to the needs of its customers.

Furthermore, major companies in the market are focusing on obtaining product approvals to gain commercial rights for the sale of their products in a particular country. This is expected to drive growth of the methicillin resistant staphylococcus aureus (MRSA) testing systems market in Europe. For instance, in January 2014, Roche announced the CE-IVD launch of the cobas MRSA/SA Test for the early, simultaneous detection of methicillin-resistant staphylococcus aureus (MRSA) and methicillin-sensitive staphylococcus aureus (SA) from nasal specimens. The cobas MRSA/SA test detects both organisms from a single specimen, providing accurate and reliable results for effective prevention and control of MRSA/SA infections. With an innovative design to include diverse geographical strain coverage, coupled with automation on the cobas 4800 System, the cobas MRSA/SA test can process specimens using a fast and advanced real-time polymerase chain reaction (PCR) amplification and detection available.

Fig.2 Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems  | Coherent Market Insights

Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market - Competitive Landscape

Key players operating in the methicillin resistant Staphylococcus aureus (MRSA) testing systems market are F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH, BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, Abbott Laboratories, Puritan Medical Products, Diatherix Eurofins, LLC, Arlington Scientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., Luminex Corporation, and R-Biopharm AG.

The methicillin-resistant staphylococcus aureus (MRSA) are different strains of Staphylococcus aureus, or ‘staph’ bacteria that are resistant to the antibiotic methicillin as well as to related beta-lactam antibiotics such as oxacillin, penicillin, amoxicillin, and cephalosporin. Methicillin-resistant Staphylococcus aureus (MRSA) testing is utilized to detect MRSAs and no other microbes. Nucleic acid amplification tests such as the polymerase chain reaction (PCR) can be used for direct detection of mecA, which is the most common gene mediating oxacillin resistance in staphylococci.

In the U.S. Methicillin is no longer commercially available. Therefore, the test is generally done to verify the presence of oxacillin, penicillin, amoxicillin, and cephalosporin resistance to confirm presence of methicillin-resistant Staphylococcus aureus (MRSA) bacteria. It is prominently employed in hospitals, especially in intensive care units to inhibit MRSA from spreading to other patients. On larger levels such as community and society, the MRSA test can be employed to detect the source of an outbreak. For a national level addition, testing and research may help scientists determine the cause.

Market Dynamics

The methicillin resistant Staphylococcus aureus (MRSA) testing systems market is expected to witness significant growth during the forecast period owing to the increasing number of product launches in the market. For instance, in July 2017, F. Hoffmann-La Roche announced the CE-IVD launch of the cobas MRSA/SA nucleic acid test for use on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) at the point of care. MRSA and SA are both major sources of healthcare and community associated infections. The cobas MRSA/SA test is designed to support rapid screening and surveillance of MRSA & SA for use in emergency rooms, intensive care units and STAT lab settings.

However, frequent product recalls are expected to hamper the methicillin resistant Staphylococcus aureus (MRSA) testing systems market growth during the forecast period. For instance, in August 2018, the U.S. Food and Drug Administration (FDA) reported that French diagnostics firm BioMerieux has recalled two of its antimicrobial susceptibility testing (AST) cards because of false results for some strains of methicillin-resistant Staphylococcus aureus (MRSA). BioMerieux initiated the recall in January 2018, for the VITEK 2 Gram Positive Cefoxitin Screen and VITEK 2 Gram Positive AST because false tests can lead to inappropriate treatment of MRSA infection and could cause severe health consequences.

Key features of the study:

  • This report provides in-depth analysis of the global methicillin resistant staphylococcus aureus (MRSA) testing systems market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global methicillin resistant staphylococcus aureus (MRSA) testing systems market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH, BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, Abbott Laboratories, Puritan Medical Products, Diatherix Eurofins, LLC, Arlington Scientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., Luminex Corporation, and R-Biopharm AG.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global methicillin resistant staphylococcus aureus (MRSA) testing systems market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for methicillin resistant Staphylococcus aureus (MRSA) testing systems market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product:
    • Instruments
    • Reagents & Kits
  • Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Test Type:
    • Immunodiagnostic Test
    • Molecular Diagnostic Test
  • Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By End User:
    • Hospitals
    • Diagnostic Laboratories
    • Academic and Research Institute
  • Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Product:
        • Instruments
        • Reagents & Kits         
      • By Test Type:
        • Immunodiagnostic Test
        • Molecular Diagnostic Test
      • By End User:
        • Hospitals
        • Diagnostic Laboratories
        • Academic and Research Institute
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Product:
        • Instruments
        • Reagents & Kits        
      • By Test Type:
        • Immunodiagnostic Test
        • Molecular Diagnostic Test
      • By End User:
        • Hospitals
        • Diagnostic Laboratories
        • Academic and Research Institute
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Product:
        • Instruments
        • Reagents & Kits
      • By Test Type:
        • Immunodiagnostic Test
        • Molecular Diagnostic Test
      • By End User:
        • Hospitals
        • Diagnostic Laboratories
        • Academic and Research Institute
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Product:
        • Instruments
        • Reagents & Kits
      • By Test Type:
        • Immunodiagnostic Test
        • Molecular Diagnostic Test
      • By End User:
        • Hospitals
        • Diagnostic Laboratories
        • Academic and Research Institute
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Product:
        • Instruments
        • Reagents & Kits
      • By Test Type:
        • Immunodiagnostic Test
        • Molecular Diagnostic Test
      • By End User:
        • Hospitals
        • Diagnostic Laboratories
        • Academic and Research Institute
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Product:
        • Instruments
        • Reagents & Kits
      • By Test Type:
        • Immunodiagnostic Test
        • Molecular Diagnostic Test
      • By End User:
        • Hospitals
        • Diagnostic Laboratories
        • Academic and Research Institute
  • Company Profiles
    • Hoffmann-La Roche*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Becton, Dickinson and Company
    • Hain Lifescience GmbH
    • BioMérieux
    • 3M Company
    • Bio-Rad Laboratories Inc.
    • Abacus Diagnostica
    • Abbott Laboratories
    • Puritan Medical Products
    • Diatherix Eurofins, LLC
    • Arlington Scientific Inc.
    • AdvanDx
    • Genspeed Biotech GmbH
    • Cepheid Inc.
    • Luminex Corporation
    • R-Biopharm AG

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product
      • Market Snippet, By Test Type
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Regulatory Scenario
    • Reimbursement Scenario
    • New Product Launches/Approvals
    • Collaborations & Partnerships
    • Mergers & Acquisitions
    • PEST Analysis
  4. Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Instruments
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Reagents & Kits
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  5. Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Test Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Immunodiagnostic Test
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Molecular Diagnostic Test
      • Introduction    
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By End User, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Diagnostic Laboratories
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Academic and Research Institutes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Product, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Product, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Product, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Product, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
    • Middle East
      • Market Size and Forecast, By Product, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Test Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Company Profiles
      • F.Hoffmann-La Roche
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Becton, Dickinson and Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hain Lifescience GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • BioMérieux
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • 3M Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bio-Rad Laboratories Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Abacus Diagnostica
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Abbott Laboratories
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Puritan Medical Products
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Diatherix Eurofins, LLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Arlington Scientific Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • AdvanDx
        •  Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Genspeed Biotech GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Cepheid Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Luminex Corporation
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • R-Biopharm AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 35 market data tables and 29 figures on "Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market” - Forecast to 2027”

Frequently Asked Questions

The CAGR of the Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems market is 10.5% during the forecast period (2020-2027).
The value of global market for methicillin resistant Staphylococcus aureus (MRSA) testing systems market is US$ 105.08 million in 2020.
The prominent players in the methicillin resistant Staphylococcus aureus (MRSA) testing systems market across the globe are F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH, BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, and Abbott Laboratories.
The methicillin resistant Staphylococcus aureus (MRSA) testing systems market is expected to be valued at US$ 211.3 million in 2027.
The methicillin resistant Staphylococcus aureus (MRSA) testing systems market is segmented into four segments on the basis of product, test type, end user and region.
The rising prevalence of methicillin resistant Staphylococcus aureus infection in hospitals, and the increasing number of product approvals and launches are expected to drive growth of the methicillin resistant Staphylococcus aureus (MRSA) testing systems market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner